Cargando…

Gene Expression Profiles Identify Biomarkers of Resistance to Decitabine in Myelodysplastic Syndromes

Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disease characterized by inefficient hematopoiesis and the potential development of acute leukemia. Among the most notable advances in the treatment of MDS is the hypomethylating agent, decitabine (5-aza-2′deoxycytidine). Although de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Seungyoun, Shin, Dong-Yeop, Kim, Dayeon, Oh, Somi, Hong, Junshik, Kim, Inho, Kim, Eunju
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700444/ https://www.ncbi.nlm.nih.gov/pubmed/34944006 http://dx.doi.org/10.3390/cells10123494

Ejemplares similares

Mechanisms of Resistance to Decitabine in the Myelodysplastic Syndrome
por: Qin, Taichun, et al.
Publicado: (2011)

Decitabine in the treatment of myelodysplastic syndromes
por: Saba, Hussain I
Publicado: (2007)

A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome
por: Jeong, Seong Hyun, et al.
Publicado: (2015)

Spotlight on decitabine for myelodysplastic syndromes in Chinese patients
por: Jing, Yu, et al.
Publicado: (2015)

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes
por: Garcia, Jacqueline S, et al.
Publicado: (2010)

Effects of decitabine on megakaryocyte maturation in patients with myelodysplastic syndromes
por: DING, KAI, et al.
Publicado: (2016)

Decitabine/cedazuridine for chronic myelomonocytic leukaemia, myelodysplastic syndromes
Publicado: (2022)

Model-based adaptive phase I trial design of post-transplant decitabine maintenance in myelodysplastic syndrome
por: Han, Seunghoon, et al.
Publicado: (2015)

Similar transplant outcomes between haploidentical and unrelated donors after reduced-intensity conditioning with busulfan, fludarabine, and anti-thymocyte globulin in patients with acute leukemia or myelodysplastic syndrome
por: Choi, Mihong, et al.
Publicado: (2020)

Small RNA sequencing profiles of mir-181 and mir-221, the most relevant microRNAs in acute myeloid leukemia
por: Lee, Yun-Gyoo, et al.
Publicado: (2019)

Clinical effect of decitabine in the treatment of myelodysplastic syndrome and influencing factors
por: Liu, Tangxia, et al.
Publicado: (2020)

Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients
por: Jung, Hyun Ae, et al.
Publicado: (2015)

Outcomes of decitabine treatment for newly diagnosed acute myeloid leukemia in older adults
por: Yoo, Kwai Han, et al.
Publicado: (2020)

Effective treatment of low-dose decitabine in myelodysplastic syndrome/myeloproliferative neoplasms
por: Ye, Xingnong, et al.
Publicado: (2017)

Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada
por: Yun, John Paul, et al.
Publicado: (2023)

Decitabine of Reduced Dosage in Chinese Patients with Myelodysplastic Syndrome: A Retrospective Analysis
por: Li, Xiao, et al.
Publicado: (2014)

P741: PATIENTS’ PERSPECTIVES ON ORAL DECITABINE AND CEDAZURIDINE FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES
por: Zeidan, Amer M., et al.
Publicado: (2023)

Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome
por: Suh, Koung Jin, et al.
Publicado: (2016)

Telomere integrated scoring system of myelodysplastic syndrome
por: Park, Hee Sue, et al.
Publicado: (2023)

Mutations in genes affecting DNA methylation enhances responses to decitabine in patients with myelodysplastic syndrome
por: Jung, Hyun Ae, et al.
Publicado: (2021)

Evaluation of Reduced-Dose Decitabine and Azacitidine for Treating Myelodysplastic Syndromes: A Retrospective Study
por: Hu, Naibo, et al.
Publicado: (2021)

Decitabine Induces Change of Biological Traits in Myelodysplastic Syndromes via FOXO1 Activation
por: Zhang, Zheng, et al.
Publicado: (2021)

Differential impact of anti-thymocyte globulin dosing by disease risk index in alternative donor peripheral blood stem cell transplantation in patients with acute leukemia or myelodysplastic syndrome after reduced intensity conditioning
por: Choi, Mihong, et al.
Publicado: (2019)

Decitabine for Treatment of Myelodysplastic Syndromes in Chinese Patients: An Open-Label, Phase-3b Study
por: Wu, Depei, et al.
Publicado: (2015)

A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome
por: Almasri, Jehad, et al.
Publicado: (2018)

Decitabine in patients with myelodysplastic syndromes: A multi‐center, open‐label, dose comparison trial
por: Liu, Hui, et al.
Publicado: (2023)

Reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for patients with myelofibrosis
por: Kim, Dong Hyun, et al.
Publicado: (2022)

Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10‐day decitabine regimen
por: Ali, Alaa M., et al.
Publicado: (2017)

Allogeneic Stem Cell Transplantation in Relapsed/Refractory Multiple Myeloma Treatment: Is It Still Relevant?
por: Park, Hyunkyung, et al.
Publicado: (2020)

Busulfan plus melphalan versus melphalan alone conditioning regimen after bortezomib based triplet induction chemotherapy for patients with newly diagnosed multiple myeloma
por: Park, Songyi, et al.
Publicado: (2021)

Association between preconditioning absolute lymphocyte count and transplant outcomes in patients undergoing matched unrelated donor allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and anti-thymocyte globulin
por: Seo, Jeongmin, et al.
Publicado: (2021)

High Cell-Free DNA Levels in Cerebrospinal Fluid Predict Leptomeningeal Seeding of Hematologic Malignancy
por: Kim, Eun Young, et al.
Publicado: (2020)

Severe pyoderma gangrenosum caused by myelodysplastic syndrome successfully treated with decitabine administered by a noncytotoxic regimen
por: Saleh, Mostafa F. M., et al.
Publicado: (2017)

Lenalidomide Plus Decitabine Treatment in a Myelodysplastic Syndrome Patient With Deletion 5q and Excess Blasts
por: Serin, Istemi, et al.
Publicado: (2020)

Distinct predictive impact of FISH abnormality in proteasome inhibitors and immunomodulatory agents response: redefining high‐risk multiple myeloma in Asian patients
por: Byun, Ja Min, et al.
Publicado: (2018)

Better treatment outcomes in patients with actively treated therapy-related myeloid neoplasms harboring a normal karyotype
por: Kim, Sang-A, et al.
Publicado: (2018)

Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
por: Savona, Michael R., et al.
Publicado: (2020)

Romiplostim plus danazol as salvage treatment for eltrombopag refractory immune thrombocytopenia: a retrospective pilot study
por: Nam, Chang Hyun, et al.
Publicado: (2021)

Serum Erythropoietin level in anemia of elderly with unclear etiology
por: Seong, Ju Yong, et al.
Publicado: (2023)

The importance of critically short telomere in myelodysplastic syndrome
por: Shin, Dong-Yeop, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e7g23depopkli24fmh7lm51mse